title: [PREVENTION AND CORRECTION OF PULMONARY COMPLICATIONS FOR SEVERE ACUTE PANCREATITIS].
abstract: Increased of proinflammatory cytokines levels, including interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNF-alpha) on severe acute pancreatitis causes vasodilatation, increased permeability of the wall, accumulation of fluid in lung tissue and pleural sinuses. Transudate from acute parapancreatyc clusters of hot liquid and abdomen falls into the chest cavity through microscopic defects in the diaphragm due to the formation of pathological pleural-peritoneal connections or the relevant pressure gradient between the abdominal and pleural cavities. Remediation and removal of acute parapancreatyc clusters combined with the use of a multicomponent drug infusion therapy Cytoflavin provide a reduction in the frequency of pulmonary complications of acute pancreatitis from 48.3 to 31.0%. Use of the drug Cytoflavin reduces the severity of endogenous intoxication and mortality from acute lung injury from 12.9 to 6.1%.
authors.forename: M B
authors.initials: MB
authors.lastname: Fedorkiv
mesh_terms: D000208:Acute Disease; D055371:Acute Lung Injury / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000378:metabolism; D002199:Capillary Permeability / Q000187:drug effects; D003964:Diaphragm / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004338:Drug Combinations; D005122:Exudates and Transudates / Q000187:drug effects; D005260:Female; D005486:Flavin Mononucleotide / Q000627:therapeutic use*; D005440:Fluid Therapy / Q000379:methods*; D006801:Humans; D007290:Inosine Diphosphate / Q000627:therapeutic use*; D016209:Interleukin-8 / Q000037:antagonists & inhibitors / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008168:Lung / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000627:therapeutic use*; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D010195:Pancreatitis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D010537:Peritoneum / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D010994:Pleura / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D020011:Protective Agents / Q000627:therapeutic use*; D013386:Succinates / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism; D014664:Vasodilation / Q000187:drug effects
chemical_list: D000975:Antioxidants; D004338:Drug Combinations; D016209:Interleukin-8; D020011:Protective Agents; D013386:Succinates; D014409:Tumor Necrosis Factor-alpha; C507879:cytoflavin; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate